undamentalytics Newsletter
Sign in

Tango Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Tango Therapeutics, Inc. had total assets of $399m, total liabilities of $52.5m and shareholders' equity of $346m. It held $112m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents28143606670112346
Receivables222————
Total current assets1944923753472663541,032
Total assets2075004364033163991,074
Accounts payable2343212
Deferred revenue (current)32263226180—
Total current liabilities41415646382220
Total debt0000000
Total liabilities1691551871491175349
Shareholders' equity393452492532003461,025
Shares outstanding——88m102m108m136m—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: SIGA vs TNGXGOSS vs TNGXNKTR vs TNGXOCUL vs TNGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Tango Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tango Therapeutics, Inc.